Nanox Vision

Company Overview

Snapshot

Founded in December 2018, Nanox Vision operates with 51–200 employees. The company has raised $345 million across 7 funding rounds and is publicly traded on NASDAQ. In February 2026, Nanox received FDA 510(k) clearance for its TAP2D image enhancement capability for its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems, advancing its regulatory strategy.

Business overview

Nanox Vision (NASDAQ: NNOX) is dedicated to transforming healthcare through preventive medical imaging technologies. The company's core offerings include Nanox.ARC, a multi-source Digital Tomosynthesis system, and Nanox.AI, an AI-based suite of algorithms designed to augment routine CT imaging for early disease detection. It also provides Nanox.CLOUD, a cloud-based software platform for imaging analysis, and Nanox.MARKETPLACE, a teleradiology services platform. Nanox serves the healthcare and medical devices industries, aiming to provide affordable, seamless end-to-end solutions from scan to diagnosis.

Strategic signal

Nanox Vision is actively expanding its global commercial footprint and technological capabilities. In June 2026, the company secured an exclusive distribution agreement to enter the Peruvian market, demonstrating its ongoing efforts to broaden the reach of its medical imaging solutions. This move signals a strategic focus on international market penetration and increased adoption of its Nanox.ARC systems.

Company Intelligence Q&A

What was a significant regulatory milestone for Nanox Vision in early 2026?

In February 2026, Nanox Vision received FDA 510(k) clearance for its TAP2D image enhancement capability, integrated into the Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. This clearance supports the company's regulatory strategy to position its systems as primary diagnostic solutions in the U.S.

What strategic partnerships did Nanox Vision announce in March 2026 to expand its global reach?

In March 2026, Nanox Vision announced collaborations with Harrison.ai to integrate AI solutions, Imperial Imaging Technology to deploy Nanox.ARC in the U.S. Southeast, and Intec SRL for exclusive distribution of Nanox.ARC in Argentina. These partnerships aim to enhance market reach and technological capabilities globally.

What was the outcome of Nanox Vision's Q4 2025 earnings call regarding its South Korean operations?

During its Q4 2025 earnings call in April 2026, Nanox Vision announced the closure of a production line in South Korea and a change in its CFO. This indicates a strategic restructuring of its manufacturing and financial leadership.

What was a key development for Nanox Vision in the European market in June 2025?

In June 2025, Nanox Vision received EU MDR CE mark certification for its HealthOST software, an AI-powered tool for bone health analysis. This certification enables commercialization across Europe and supports early detection of musculoskeletal diseases like osteoporosis.

What was the outcome of Nvidia's investment portfolio reshuffle in February 2025 concerning Nanox Vision?

In February 2025, Nvidia sold its stake in Nanox Vision as part of a portfolio reshuffle, which also included divesting from. This decision led to a decline in Nanox Vision's stock price, reflecting a strategic shift in Nvidia's investment focus.